人组织型激肽释放酶6在卵巢上皮性肿瘤中的表达及其与临床病理特征和预后的关系

Objective To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer. Methods The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer. Results The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in higher-grade ovarian cancer tissues (68.4%) was higher than that in low-grade ones (14.3%, P<0.05). The expression of hK6 in late-stage (stage Ⅲ ,76.7%) was significantly higher than that in early-stage (stage Ⅰ or Ⅱ ,26.7%, P < 0.01). The expression of hK6 was significantly higher in patients with lymph node metastasis (77.8%) than that in patients without (33.3% ,P<0.01). The expression of hK6 in the cancer tissues in the patients died, or with reeeurence or metastasis within 3 years after surgery was higher (75.0%) than that in the patients with stable disease (42.9%, P < 0. 05). Conclusion The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis, hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.     

人组织型激肽释放酶6在卵巢上皮性肿瘤中的表达及其与临床病理特征和预后的关系

Objective To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer. Methods The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer. Results The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in higher-grade ovarian cancer tissues (68.4%) was higher than that in low-grade ones (14.3%, P<0.05). The expression of hK6 in late-stage (stage Ⅲ ,76.7%) was significantly higher than that in early-stage (stage Ⅰ or Ⅱ ,26.7%, P < 0.01). The expression of hK6 was significantly higher in patients with lymph node metastasis (77.8%) than that in patients without (33.3% ,P<0.01). The expression of hK6 in the cancer tissues in the patients died, or with reeeurence or metastasis within 3 years after surgery was higher (75.0%) than that in the patients with stable disease (42.9%, P < 0. 05). Conclusion The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis, hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.     

人组织型激肽释放酶6在卵巢上皮性肿瘤中的表达及其与临床病理特征和预后的关系

Objective To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer. Methods The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer. Results The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in higher-grade ovarian cancer tissues (68.4%) was higher than that in low-grade ones (14.3%, P<0.05). The expression of hK6 in late-stage (stage Ⅲ ,76.7%) was significantly higher than that in early-stage (stage Ⅰ or Ⅱ ,26.7%, P < 0.01). The expression of hK6 was significantly higher in patients with lymph node metastasis (77.8%) than that in patients without (33.3% ,P<0.01). The expression of hK6 in the cancer tissues in the patients died, or with reeeurence or metastasis within 3 years after surgery was higher (75.0%) than that in the patients with stable disease (42.9%, P < 0. 05). Conclusion The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis, hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.     

人组织型激肽释放酶6在卵巢上皮性肿瘤中的表达及其与临床病理特征和预后的关系

Objective To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer. Methods The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer. Results The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in higher-grade ovarian cancer tissues (68.4%) was higher than that in low-grade ones (14.3%, P<0.05). The expression of hK6 in late-stage (stage Ⅲ ,76.7%) was significantly higher than that in early-stage (stage Ⅰ or Ⅱ ,26.7%, P < 0.01). The expression of hK6 was significantly higher in patients with lymph node metastasis (77.8%) than that in patients without (33.3% ,P<0.01). The expression of hK6 in the cancer tissues in the patients died, or with reeeurence or metastasis within 3 years after surgery was higher (75.0%) than that in the patients with stable disease (42.9%, P < 0. 05). Conclusion The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis, hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.     

人组织型激肽释放酶6在卵巢上皮性肿瘤中的表达及其与临床病理特征和预后的关系

Objective To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer. Methods The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer. Results The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in higher-grade ovarian cancer tissues (68.4%) was higher than that in low-grade ones (14.3%, P<0.05). The expression of hK6 in late-stage (stage Ⅲ ,76.7%) was significantly higher than that in early-stage (stage Ⅰ or Ⅱ ,26.7%, P < 0.01). The expression of hK6 was significantly higher in patients with lymph node metastasis (77.8%) than that in patients without (33.3% ,P<0.01). The expression of hK6 in the cancer tissues in the patients died, or with reeeurence or metastasis within 3 years after surgery was higher (75.0%) than that in the patients with stable disease (42.9%, P < 0. 05). Conclusion The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis, hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.     

人组织型激肽释放酶6在卵巢上皮性肿瘤中的表达及其与临床病理特征和预后的关系

Objective To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer. Methods The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer. Results The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in higher-grade ovarian cancer tissues (68.4%) was higher than that in low-grade ones (14.3%, P<0.05). The expression of hK6 in late-stage (stage Ⅲ ,76.7%) was significantly higher than that in early-stage (stage Ⅰ or Ⅱ ,26.7%, P < 0.01). The expression of hK6 was significantly higher in patients with lymph node metastasis (77.8%) than that in patients without (33.3% ,P<0.01). The expression of hK6 in the cancer tissues in the patients died, or with reeeurence or metastasis within 3 years after surgery was higher (75.0%) than that in the patients with stable disease (42.9%, P < 0. 05). Conclusion The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis, hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.     

人组织型激肽释放酶6在卵巢上皮性肿瘤中的表达及其与临床病理特征和预后的关系

Objective To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer. Methods The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer. Results The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in higher-grade ovarian cancer tissues (68.4%) was higher than that in low-grade ones (14.3%, P<0.05). The expression of hK6 in late-stage (stage Ⅲ ,76.7%) was significantly higher than that in early-stage (stage Ⅰ or Ⅱ ,26.7%, P < 0.01). The expression of hK6 was significantly higher in patients with lymph node metastasis (77.8%) than that in patients without (33.3% ,P<0.01). The expression of hK6 in the cancer tissues in the patients died, or with reeeurence or metastasis within 3 years after surgery was higher (75.0%) than that in the patients with stable disease (42.9%, P < 0. 05). Conclusion The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis, hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.     

人组织型激肽释放酶6在卵巢上皮性肿瘤中的表达及其与临床病理特征和预后的关系

Objective To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer. Methods The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer. Results The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in higher-grade ovarian cancer tissues (68.4%) was higher than that in low-grade ones (14.3%, P<0.05). The expression of hK6 in late-stage (stage Ⅲ ,76.7%) was significantly higher than that in early-stage (stage Ⅰ or Ⅱ ,26.7%, P < 0.01). The expression of hK6 was significantly higher in patients with lymph node metastasis (77.8%) than that in patients without (33.3% ,P<0.01). The expression of hK6 in the cancer tissues in the patients died, or with reeeurence or metastasis within 3 years after surgery was higher (75.0%) than that in the patients with stable disease (42.9%, P < 0. 05). Conclusion The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis, hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.     

人组织型激肽释放酶6在卵巢上皮性肿瘤中的表达及其与临床病理特征和预后的关系

Objective To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer. Methods The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer. Results The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in higher-grade ovarian cancer tissues (68.4%) was higher than that in low-grade ones (14.3%, P<0.05). The expression of hK6 in late-stage (stage Ⅲ ,76.7%) was significantly higher than that in early-stage (stage Ⅰ or Ⅱ ,26.7%, P < 0.01). The expression of hK6 was significantly higher in patients with lymph node metastasis (77.8%) than that in patients without (33.3% ,P<0.01). The expression of hK6 in the cancer tissues in the patients died, or with reeeurence or metastasis within 3 years after surgery was higher (75.0%) than that in the patients with stable disease (42.9%, P < 0. 05). Conclusion The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis, hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.     

DETECTING EXPRESSION OF MRP-1/CD9 mRNA IN LUNG CANCERS USING TISSUE MICROARRAYS AND FLUORESCENCE IN SITU HYBRIDIZATION METHODS

Objective： The aim of this study was to investigate the MRP-1/CD9mRNA expression in lung cancer and normal lung tissues and the relationship between its expression and pathologic grades, clinical stages, metastasis and prognosis. Methods： To observe MRP-1/C9mRNA expression, tissue microarray （TMA） containing 54 lung cancers and 10 normal lung tissues was prepared and Fluorescence in situ hybridization was used. Results： The positive rate of MRP-1/CD9 expression was 48.1% in lung cancer, lower than that of normal lung tissues. The statistical difference was significant （P〈0.05）. Its protein expression had no relationship with the patients＇ ages, sex and the macroscopic type of tumor, but had relationships with the histological type, clinical stage, differentiated degree and metastasis. The expression in non-small cell lung cancer （NSCLC） was higher than that in small cell lung cancer （SCLC）; in well-moderately differentiated group was higher than that in poorly differentiated group; Earlier period group （I＋II） was higher than in later period group （Ⅲ＋Ⅳ）; and in group without lymphoid metastasis was higher than in patients with lymphoid metastasis. Conclusion： The progression of the lung cancer maybe related with the descended MRP-1/Cd9 expression, which may be useful in evaluating the prognosis of cancer patients.     

周期蛋白6在DNA复制、细胞周期检测点和肿瘤发生发展中的作用

周期蛋白6(CDC6)是组成前复制复合物(Pre-RC)的主要蛋白之一,控制细胞从G1期进入S期,同时也参与激活和维持有丝分裂S-M期检测点机制.最近的研究发现其也具有原癌基因的特性,并在人多种肿瘤细胞中存在高表达,对肿瘤发生发展起重要作用.CDC6致癌机制可能与INK4/ARF连结物信号途径和(或)某些替代机制有关.     

周期蛋白6在DNA复制、细胞周期检测点和肿瘤发生发展中的作用

周期蛋白6(CDC6)是组成前复制复合物(Pre-RC)的主要蛋白之一,控制细胞从G1期进入S期,同时也参与激活和维持有丝分裂S-M期检测点机制.最近的研究发现其也具有原癌基因的特性,并在人多种肿瘤细胞中存在高表达,对肿瘤发生发展起重要作用.CDC6致癌机制可能与INK4/ARF连结物信号途径和(或)某些替代机制有关.     

周期蛋白6在DNA复制、细胞周期检测点和肿瘤发生发展中的作用

周期蛋白6(CDC6)是组成前复制复合物(Pre-RC)的主要蛋白之一,控制细胞从G1期进入S期,同时也参与激活和维持有丝分裂S-M期检测点机制.最近的研究发现其也具有原癌基因的特性,并在人多种肿瘤细胞中存在高表达,对肿瘤发生发展起重要作用.CDC6致癌机制可能与INK4/ARF连结物信号途径和(或)某些替代机制有关.     

周期蛋白6在DNA复制、细胞周期检测点和肿瘤发生发展中的作用

周期蛋白6(CDC6)是组成前复制复合物(Pre-RC)的主要蛋白之一,控制细胞从G1期进入S期,同时也参与激活和维持有丝分裂S-M期检测点机制.最近的研究发现其也具有原癌基因的特性,并在人多种肿瘤细胞中存在高表达,对肿瘤发生发展起重要作用.CDC6致癌机制可能与INK4/ARF连结物信号途径和(或)某些替代机制有关.     

周期蛋白6在DNA复制、细胞周期检测点和肿瘤发生发展中的作用

周期蛋白6(CDC6)是组成前复制复合物(Pre-RC)的主要蛋白之一,控制细胞从G1期进入S期,同时也参与激活和维持有丝分裂S-M期检测点机制.最近的研究发现其也具有原癌基因的特性,并在人多种肿瘤细胞中存在高表达,对肿瘤发生发展起重要作用.CDC6致癌机制可能与INK4/ARF连结物信号途径和(或)某些替代机制有关.     

周期蛋白6在DNA复制、细胞周期检测点和肿瘤发生发展中的作用

周期蛋白6(CDC6)是组成前复制复合物(Pre-RC)的主要蛋白之一,控制细胞从G1期进入S期,同时也参与激活和维持有丝分裂S-M期检测点机制.最近的研究发现其也具有原癌基因的特性,并在人多种肿瘤细胞中存在高表达,对肿瘤发生发展起重要作用.CDC6致癌机制可能与INK4/ARF连结物信号途径和(或)某些替代机制有关.     

周期蛋白6在DNA复制、细胞周期检测点和肿瘤发生发展中的作用

周期蛋白6(CDC6)是组成前复制复合物(Pre-RC)的主要蛋白之一,控制细胞从G1期进入S期,同时也参与激活和维持有丝分裂S-M期检测点机制.最近的研究发现其也具有原癌基因的特性,并在人多种肿瘤细胞中存在高表达,对肿瘤发生发展起重要作用.CDC6致癌机制可能与INK4/ARF连结物信号途径和(或)某些替代机制有关.     

周期蛋白6在DNA复制、细胞周期检测点和肿瘤发生发展中的作用

周期蛋白6(CDC6)是组成前复制复合物(Pre-RC)的主要蛋白之一,控制细胞从G1期进入S期,同时也参与激活和维持有丝分裂S-M期检测点机制.最近的研究发现其也具有原癌基因的特性,并在人多种肿瘤细胞中存在高表达,对肿瘤发生发展起重要作用.CDC6致癌机制可能与INK4/ARF连结物信号途径和(或)某些替代机制有关.     

Mouse Anti-human Interleukin-6 Receptor Monoclonal Antibody Inhibits Proliferation of Fresh Human Myeloma Cells in vitro

Interleukin-6 (IL-6) is a major growth factor in multiple myeloma. We investigated the effect of mouse anti-human IL-6 receptor monoclonal antibody (anti-IL-6R mAb) on the in vitro proliferation of freshly isolated myeloma cells from 21 patients to evaluate the therapeutic potential. The addition of anti-IL-6R mAb inhibited more than 30% of the spontaneous proliferation of myeloma cells in 9 of 21 cases in a dose- (0.1 to 20 / μ /ml) and time-dependent manner. The inhibitory effects of anti-IL-6R mAb did not differ significantly from that of anti-IL-6 mAb, and were correlated with the extent of the response of myeloma cells to IL-6. Flow cytometric analysis showed that all myeloma cells expressed IL-6R, whose intensity was not correlated with either the extent of response of myeloma cells to IL-6 or the inhibitory effects of anti-IL-6R mAb on proliferation of myeloma cells. Although our study showed heterogeneity in the proliferative responses of myeloma cells to IL-6 and anti-IL-6R mAb, these observations suggest the possibility of using anti-IL-6R mAbs for treating some patients with multiple myeloma whose growth depends on IL-6.